• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MOV.AI appoints Liat Soffer as CFO to support scaling its business

    11/8/21 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email

    TEL AVIV, Israel and LISBON, Portugal, Nov. 8, 2021 /PRNewswire/ -- MOV.AI, developer of the revolutionary Robotics Engine PlatformTM, today announced the recent addition of Liat Soffer to its management team, as Chief Financial Officer (CFO).

    Soffer is a seasoned financial executive with over 25 years of experience in finance, accounting, and business leadership. She has a proven track record of scaling start-up operations in the software domain, guiding them all the way from early-stage funding to IPOs.

    "Following the recent launch of the Robotics Engine PlatformTM, MOV.AI has been experiencing strong traction and growth, and we are scaling our operations rapidly," says Motti Kushnir, MOV.AI CEO. "Liat is an experienced CFO that has guided the growth of several successful hi-tech companies. She brings a wealth of experience that will help us achieve our goals and deliver great results to both our customers and investors."

    "I am excited to join the MOV.AI team," said Liat Soffer, newly appointed CFO, MOV.AI. "I am passionate about providing real value and driving growth. MOV.AI has great potential based on its technology - a game changer in a market that is forecast to experience tremendous growth - its leadership team and its vision. I look forward to helping make this vision a reality.

    Before joining MOV.AI Liat was CFO at CyberX (Acquired by Microsoft (MSFT),  ForeScout Technologies, Pango Mobile Parking (Sold to Parking by Phone), BrainStorm Cell Therapeutics (NASDAQ:BCLI), and others.

    Liat is also a strong proponent of inclusion and promoting women in technology. As a mentor in the Woman2Woman mentoring program, she is helping women in hi tech reach their full potential. She is also active in the Special Olympics.

    About MOV.AI

    MOV.AI is changing AMRs as we know them.

    It provides AMR manufacturers and integrators with the tools they need to create great robots quickly, allowing users to benefit from automation products that are as flexible as the age we live in.

    Born out of an unmet need, MOV.AI is a ROS-based Robotics Engine PlatformTM packaged in an intuitive web-based interface. It contains everything needed to build, deploy and operate intelligent robots. MOV.AI completely changes the way Autonomous Mobile Robots are developed, in terms of time to market, cost and flexibility.

    Media contact

    Ruth Zamir

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/movai-appoints-liat-soffer-as-cfo-to-support-scaling-its-business-301418412.html

    SOURCE MOV.AI

    Get the next $BCLI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    10/2/24 8:00:14 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

    4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    7/31/24 4:09:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

    4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    7/31/24 4:08:32 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainstorm Cell upgraded by Maxim Group

    Maxim Group upgraded Brainstorm Cell from Hold to Buy

    2/5/21 8:55:41 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

    Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

    2/4/21 1:51:23 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    SEC Filings

    View All

    SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc.

    10-Q - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    8/14/25 8:00:50 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    8/14/25 7:50:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form RW filed by Brainstorm Cell Therapeutics Inc.

    RW - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    7/22/25 4:18:42 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confir

    8/14/25 7:02:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

    Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call.  Following the

    8/8/25 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB

    NEW YORK, July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm's common stock on Nasdaq will be suspended at the open of trading on July 18, 2025. The delisting is a result of the company's non-compliance with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement. BrainStorm has already secured approval for its common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipat

    7/17/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Dagher Ibrahim B. was granted 50,000 shares, increasing direct ownership by 297% to 66,849 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    1/7/25 4:11:08 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: New insider Dagher Ibrahim B. claimed ownership of 505,742 shares (SEC Form 3)

    3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    1/7/25 4:10:10 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Lebovits Chaim was granted 120,000 shares, increasing direct ownership by 148% to 200,960 units (SEC Form 4)

    4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

    1/3/25 5:36:42 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/14/24 3:24:53 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/13/24 7:55:51 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

    SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    2/12/24 10:06:24 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confir

    8/14/25 7:02:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

    Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call.  Following the

    8/8/25 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

    Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

    5/19/25 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

    Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

    6/20/24 6:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

    Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

    7/12/23 7:00:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

    NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further

    6/20/23 9:06:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care